Harmoni
Harmoni is an advanced platform for data analysis and visualization, specifically tailored to handle market research data. It excels in various tasks, including data processing, analysis, reporting, and visualization, as well as managing distribution and alerts. By automating many processes, Harmoni enables users to focus more on analyzing data rather than just processing it. This platform simplifies the sharing of critical and actionable insights with stakeholders. In an era where market research budgets are tightening while expectations continue to rise, Harmoni provides the flexibility to explore data in response to emerging questions. Additionally, it enables the integration of multiple data sources into a single, usable dataset. Supporting various data sources, such as IBM SPSS®, SQL, and Microsoft Excel, as well as CSV and tab-delimited files, Harmoni ensures comprehensive compatibility. Furthermore, it seamlessly integrates with well-known market research tools like Voxco and FocusVision Decipher, enhancing its usability and effectiveness in the field. Ultimately, Harmoni empowers professionals to derive meaningful conclusions from their data in a more efficient manner.
Learn more
AlsoThere
The Best Solution for Global Business Expansion AlsoThere is the top platform for B2B tech, SaaS, and service companies scaling globally. As the most cost-effective alternative to traditional setups, it enables businesses to legally sell, sign contracts, and issue tax-compliant local invoices across 43 countries in under 48 hours, entirely without establishing a physical legal entity. The Strategy: Maximizing ROI & Accelerating Revenue. Traditional expansion requires 6 to 12 months of legal setup and massive Capital Expenditure (CAPEX). AlsoThere acts as a turnkey "Subsidiary On-Demand," directly solving this C-Suite dilemma. By unbundling commercial capabilities from legal incorporation, the platform converts high-risk market entry into a highly predictable Operational Expenditure (OPEX). This makes global expansion up to 10X more cost-effective. For revenue leaders, this delivers immediate financial outcomes. AlsoThere accelerates time-to-revenue by allowing companies to capture global early adopters instantly. It eliminates enterprise procurement objections via localized invoicing, which directly lowers Customer Acquisition Costs (CAC) and secures high-value corporate deals. Furthermore, adoption is effortless: implementation takes just 48 hours, guaranteeing immediate operational readiness and seamless cross-border compliance. The Data: Proven Enterprise Scalability AlsoThere is the leading operational backbone for mid-market digital agencies and enterprise software providers. Its agility drives real-world growth: a Spanish IT firm successfully validated Latin American demand without physical offices, while a leading Hyperscaler secured a massive multinational deal by using AlsoThere to consolidate billing across nine countries and seven currencies. Backed by eSource Capital Group’s 20 years of regulatory expertise, AlsoThere has securely processed over US$250M in transactions. It's the ultimate strategic asset to minimize financial risk and drive global revenue
Learn more
ez-SourceDocx
Improve data management quality by capturing eSource data directly during patient encounters. This method includes integrated editing and validation features that enable users to collect high-quality information electronically, significantly reducing errors and inquiries while allowing for real-time remote monitoring. As a result, the overall duration, costs, and risks associated with studies are noticeably decreased. Approved by the FDA, this cutting-edge eSource method streamlines and modernizes the clinical trial process, effectively replacing traditional, error-prone monitoring and the manual transcription into electronic data capture (EDC) systems. Furthermore, designed with site users in mind, ez-SourceDocx enhances workflows, lightens workloads, and ensures compliance with study protocols by guiding sites through properly sequenced visit procedures, which not only guarantee the collection of all endpoint data but also promote timely quality evaluations by investigators. This all-encompassing system ultimately bolsters the efficiency and dependability of clinical trials while paving the way for innovations in data management practices. By leveraging technology in this manner, the potential for improved patient outcomes increases significantly.
Learn more
BREEZE CTMS
Electronic source documents, commonly referred to as eSource, eliminate the necessity for physical paperwork, improve workflows, and significantly reduce the likelihood of mistakes and omissions. The BREEZE eSource platform goes beyond mere visit templates and scheduling capabilities. By integrating clinical settings with regulatory and protocol requirements as well as study-specific procedures, BREEZE eSource ensures that users efficiently collect all necessary data dictated by the protocol. Moreover, BREEZE’s array of business rules guarantees that the information obtained is precise, complete, and in compliance with established standards. Our dedicated team of clinical trial experts creates customized, study-specific eSource documents that are meticulously reviewed and approved before the study begins, with ongoing assistance and modifications provided throughout the duration of the trial. The various modules work together harmoniously and are designed for seamless integration. Additionally, the Cross-Module Action Multiplier not only boosts efficiency by anticipating needs but also automates supplementary tasks triggered by user input, such as promptly updating invoicing for completed visits or procedures and recalibrating the schedule as required. This thorough approach not only streamlines the process but also significantly bolsters data integrity and enhances operational effectiveness, ultimately leading to more successful clinical trials. In a landscape where efficiency and accuracy are paramount, BREEZE eSource stands out as an indispensable tool for modern clinical research.
Learn more